Cercar
01/11/2025
Wolf's isotopic phenomenon in a patient with T-cell lymphoblastic lymphoma
Vilaseca, VG, Perez, ES, Fabrego, IE, Peral, IL, Prat, AM. Wolf's isotopic phenomenon in a patient with T-cell lymphoblastic lymphoma. MEDICINA CLINICA. 2025; 165(5)DOI:10.1016/j.medcli.2025.107073. PMID:40543401. IF:2.100(Q2/3D).
01/10/2025
Evaluation of Clinical Outcomes and Treatment Complications in Hairy Cell Leukemia: A Single-Center Retrospective Analysis
Fasanella, MG, Mozos, A, Briones, J, Nomdedeu, JF, Novelli, S. Evaluation of Clinical Outcomes and Treatment Complications in Hairy Cell Leukemia: A Single-Center Retrospective Analysis. Cancer Reports. 2025; 8(10)DOI:10.1002/cnr2.70356. PMID:41031578. IF:(Q/D).
01/10/2025
Frailty dynamics and their impact on QoL in patients undergoing autologous HCT for multiple myeloma: Results from a multicentre GETH-TC study
Tolosa-Ridao, C, González, MB, Gómez, MA, Fox, L, Artigas, MDP, Santamaria, A, González, MDQ, Salinas, AS, Camacho, JMS, Alvaro, VI, Abdallahi-Lefdil, Z, Navascues, JC, Pardo, L, Fernández-Luis, S, Suárez, LPV, Villar, S, Beorlegui-Murillo, P, Esquirol, A, García, II, Ribes-Amorós, J, Lavilla, E, Lopez-Marín, J, Basalobre, P, Filaferro, S, Cedillo, A, Bento, L, Sureda, A, Salas, MQ. Frailty dynamics and their impact on QoL in patients undergoing autologous HCT for multiple myeloma: Results from a multicentre GETH-TC study. BRITISH JOURNAL OF HAEMATOLOGY. 2025; 207(4)DOI:10.1111/bjh.70068. PMID:40796522. IF:3.800(Q1/3D).
30/09/2025
Non-Competitive Binding of Isatuximab and Daratumumab to CD38: Implications for Targeted Therapy in Multiple Myeloma
Osuna-Gómez, R, López-Pardo, J, Mulet, M, Nomdedéu, J, Cantó, E, Ortin, R, Cayuela, AS, Ortiz, MA, Guinart-Cuadra, A, Vidal, S. Non-Competitive Binding of Isatuximab and Daratumumab to CD38: Implications for Targeted Therapy in Multiple Myeloma. Pharmaceutics. 2025; 17(10)DOI:10.3390/pharmaceutics17101278. PMID:41155915. IF:5.500(Q1/1D).
26/09/2025
Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation
Torrent-Rodríguez, A, Cascos, E, Garcés, VN, Pérez-López, E, Baile-González, M, Rodríguez, CM, Cascón, MJP, Luque, M, Esquirol, A, Calvo, CM, Peña-Muñoz, F, Fernando, IH, Ormtegi, IO, Marín, AJS, Fernández-Luis, S, Domínguez-García, JJ, Fernández, SV, Lorenzo, JLL, Girón, MFD, Pinedo, LG, García-Maño, L, González-Rodriguez, AP, Torrado, T, Filaferro, S, Basalobre, P, Ortí, G, Rovira, M, Chacón, MJ, Salas, MQ. Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation. Cancers. 2025; 17(19)DOI:10.3390/cancers17193128. PMID:41097656. IF:4.400(Q2/3D).
22/09/2025
Prevalence of Fms-Like Tyrosine Kinase 3 (FLT3) Mutations in Patients With Acute Myeloid Leukaemia: A Systematic Literature Review and Meta-Analysis
Lewis, JFM, Daver, NG, Robinson, NJ, Pandya, BJ, Pierre-Louis, B, Monir, S, Sierra, J. Prevalence of Fms-Like Tyrosine Kinase 3 (FLT3) Mutations in Patients With Acute Myeloid Leukaemia: A Systematic Literature Review and Meta-Analysis. Cancer Medicine. 2025; 14(18)DOI:10.1002/cam4.71205. PMID:40981231. IF:3.100(Q2/5D).